Major drug approvals for cancer and rare diseases highlight advances, while emerging health concerns about caffeine and artificial sweeteners gain attention.

Datopotamab deruxtecan, an antibody drug conjugate, received FDA approval for treating certain patients with triple-negative breast cancer, expanding therapeutic options for this aggressive cancer type.

The European Medicines Agency approved a new oral therapy for idiopathic and progressive pulmonary fibrosis, addressing fibrotic lung diseases that previously had limited treatment options available.

EMA granted conditional authorization for the first drug to treat PIK3CA-related overgrowth disorders in children aged 2 and older and adults, addressing a previously untreated severe condition.

Despite FDA rejection, the EMA recommended camizestrant, a new breast cancer SERD, after phase 3 data demonstrated longer progression-free survival when combined with CDK4/6 inhibitors for switching therapy.

Research shows maternal chikungunya infection during pregnancy significantly increases infant hospitalization risk through age 3, informing global surveillance and vaccination strategy development.

A study found higher caffeine intake correlates with greater depression severity, though caffeine may paradoxically reduce the association between depression and severe insomnia.

Novel CRISPR-Cas9 gene-editing treatments show promise as potential one-time cures for cardiovascular disease, though researchers emphasize that establishing long-term safety data will require years of additional study.

Emerging evidence indicates artificial sugar substitutes may negatively affect metabolism, gut microbiome composition, and cardiovascular health more substantially than previously understood, raising new health concerns.